Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| NET LOSS | $(18,582) | $(21,479) |
| Other comprehensive loss, net of tax: | ||
| Foreign currency translation adjustment | 189 | 353 |
| Unrealized gain on marketable debt securities | 3 | 150 |
| COMPREHENSIVE LOSS | (18,390) | (20,976) |
| Less: Comprehensive (income) loss attributable to noncontrolling interest | (27) | (7) |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE COMMON SHAREHOLDERS | $(18,417) | $(20,983) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.